United Kingdom · Question · Written question
HL HL4912
Immunosuppression: Coronavirus
Introduced
19 January 2023
Last action
8 February 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
8 February 2023
Summary
To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 7 June 2022 (HL500), which advisory body reviewed the National Institute for Health and Care Research rapid study on those who remain vulnerable to poor outcomes from COVID-1
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
19 January 2023
Written question
To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 7 June 2022 (HL500), which advisory body reviewed the National Institute for Health and Care Research rapid study on those who remain vulnerable to poor outcomes from COVID-1
Source: Lords
8 February 2023
Answer
The Therapeutics Clinical Review Panel periodically reviews new evidence on the definition and revision of eligible cohorts from COVID-19 therapeutics from several sources, including clinical evidence, expert groups and external stakeholders. The Panel me...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-01-19/HL4912
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1568855
- uk · wq-1568855 · source updated 8 February 2023